CGON vs. ACLX, IMCR, DNLI, VCEL, KYMR, APGE, SANA, SWTX, RXRX, and IOVA
Should you be buying CG Oncology stock or one of its competitors? The main competitors of CG Oncology include Arcellx (ACLX), Immunocore (IMCR), Denali Therapeutics (DNLI), Vericel (VCEL), Kymera Therapeutics (KYMR), Apogee Therapeutics (APGE), Sana Biotechnology (SANA), SpringWorks Therapeutics (SWTX), Recursion Pharmaceuticals (RXRX), and Iovance Biotherapeutics (IOVA). These companies are all part of the "biological products, except diagnostic" industry.
Arcellx (NASDAQ:ACLX) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.
Arcellx received 35 more outperform votes than CG Oncology when rated by MarketBeat users. However, 77.78% of users gave CG Oncology an outperform vote while only 75.00% of users gave Arcellx an outperform vote.
In the previous week, Arcellx had 4 more articles in the media than CG Oncology. MarketBeat recorded 19 mentions for Arcellx and 15 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.47 beat Arcellx's score of 0.11 indicating that Arcellx is being referred to more favorably in the media.
96.0% of Arcellx shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 6.2% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Arcellx currently has a consensus target price of $78.20, suggesting a potential upside of 57.22%. CG Oncology has a consensus target price of $61.75, suggesting a potential upside of 116.67%. Given Arcellx's higher possible upside, analysts clearly believe CG Oncology is more favorable than Arcellx.
CG Oncology has a net margin of 0.00% compared to CG Oncology's net margin of -64.08%. Arcellx's return on equity of 0.00% beat CG Oncology's return on equity.
CG Oncology has lower revenue, but higher earnings than Arcellx.
Summary
Arcellx beats CG Oncology on 8 of the 15 factors compared between the two stocks.
Get CG Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CG Oncology Competitors List
Related Companies and Tools
